NBIX vs PTCT · P/E 45, rev $1.77B vs rev $633.1M
Neurocrine Biosciences Inc (NBIX) versus PTC Therapeutics Inc (PTCT) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
PTC Therapeutics Inc (PTCT) is a biotechnology company listed on NASDAQ.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported PTCT revenue for 2026-06-30 was $633.1M. Net income was $80.7M. PTCT currently screens at market cap $6.51B.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. PTCT currently screens at market cap $6.51B.
Not investment advice. Open the NBIX and PTCT stock pages for the full models.
Not investment advice.